Literature DB >> 25554967

Prospective evaluation of quality-of-life improvement after correction of the alar base in the flaccidly paralyzed face.

Robin W Lindsay1, Prabhat Bhama1, Marc Hohman2, Tessa A Hadlock1.   

Abstract

IMPORTANCE: Nasal valve collapse caused by facial palsy is an often overlooked but disturbing sequela of flaccid facial paralysis.
OBJECTIVE: To prospectively study the effect of fascia lata sling placement for correction of external nasal valve compromise in patients with flaccid facial paralysis, using a validated disease-specific quality-of-life outcome survey. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective study of 68 patients from March 2009 to December 2013 who underwent fascia lata sling placement for correction of external nasal valve compromise. INTERVENTION: Fascia lata sling placement for the correction of external nasal valve compromise . MAIN OUTCOME AND MEASURE: Nasal Obstruction Symptom Evaluation (NOSE) scale.
RESULTS: Sixty-eight disease-specific quality-of-life determinations were performed using the NOSE scale. Ratings were ascertained preoperatively and postoperatively. Sixty patients completed a NOSE scale prior to surgical intervention, and 40 completed the survey after intervention. There was a statistically significant difference in NOSE scores after fascia lata sling placement The mean preoperative NOSE score was 37.6 (27.1), and the mean postoperative score was 16.6 (17.37) (Wilcoxon signed-rank test; P < .001). All patients had improvement in their nasal obstruction, which persisted uniformly in follow-up. CONCLUSIONS AND RELEVANCE: The nasal valve is a zone that has historically been neglected, despite the fact that a highly effective surgical solution has existed for decades. We highlight the significance of nasal valve dysfunction in patients with flaccid facial paralysis, demonstrate a quantitative benefit in disease-specific quality of life after fascia late sling placement for external nasal valve compromise, and suggest an updated treatment algorithm. This method offers a predictably successful, straightforward surgical solution to an overlooked functional problem in the patient with flaccid facial paralysis. LEVEL OF EVIDENCE: 4.

Entities:  

Mesh:

Year:  2015        PMID: 25554967     DOI: 10.1001/jamafacial.2014.1295

Source DB:  PubMed          Journal:  JAMA Facial Plast Surg        ISSN: 2168-6076            Impact factor:   4.611


  5 in total

1.  Speech and Communicative Participation in Patients With Facial Paralysis.

Authors:  James H Kim; Laurel M Fisher; Lindsay Reder; Edie R Hapner; Jon-Paul Pepper
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-08-01       Impact factor: 6.223

Review 2.  Management of the facial nerve in parotid cancer: preservation or resection and reconstruction.

Authors:  Orlando Guntinas-Lichius; Carl E Silver; Jovanna Thielker; Manuel Bernal-Sprekelsen; Carol R Bradford; Remco De Bree; Luis P Kowalski; Kerry D Olsen; Miquel Quer; Alessandra Rinaldo; Juan R Rodrigo; Alvaro Sanabria; Ashok R Shaha; Robert P Takes; Vincent Vander Poorten; Peter Zbären; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-09-28       Impact factor: 2.503

3.  Toward the Bionic Face: A Novel Neuroprosthetic Device Paradigm for Facial Reanimation Consisting of Neural Blockade and Functional Electrical Stimulation.

Authors:  Nate Jowett; Robert E Kearney; Christopher J Knox; Tessa A Hadlock
Journal:  Plast Reconstr Surg       Date:  2019-01       Impact factor: 4.730

4.  Evaluation of Societal Health Utility of Facial Palsy and Facial Reanimation.

Authors:  Callum Faris; Oren Tessler; Alyssa Heiser; Tessa Hadlock; Nate Jowett
Journal:  JAMA Facial Plast Surg       Date:  2018-12-01       Impact factor: 4.611

5.  Human Induced Pluripotent Stem Cell-Derived Motor Neuron Transplant for Neuromuscular Atrophy in a Mouse Model of Sciatic Nerve Injury.

Authors:  Jon-Paul Pepper; Tiffany V Wang; Valerie Hennes; Soo Yeon Sun; Justin K Ichida
Journal:  JAMA Facial Plast Surg       Date:  2017-05-01       Impact factor: 4.611

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.